focus -WSS

focus

author：entertainment 2025-09-06 06:17:08 - browse：429

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Readout LOUD podcast: ALS dilemma, first MASH drug, and more

WSS

How many hemophilia patients actually want gene therapy?

EPA limits use of carcinogenic gas for sterilizing medical devices

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Steward Health Care Massachusetts hospitals face fiscal disaster

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

focus

explore

Medicare proposal to cover medical devices draws a mixed reaction

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pushing for an NIH office for post

As demand for Covid shots wanes, Moderna seeks its next success

The leaders of Italy and Poland say European Union should focus on stopping migration

Psychedelics group wrestles with new pharma identity

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

George Santos makes 1st court appearance after pleading not guilty to 13 counts

First U.S. drug developed to treat liver disease MASH is approved

leisure time

Boston's new lab space is opening empty

Change Healthcare outage fallout shows need for new oversight

RaDonda Vaught links Vanderbilt hospital issues to patient death

Pentagon will tighten controls on classified information after Discord leak

Amid AI frenzy, a top HHS official's quest to create safeguards

Condition critical? Britain's beloved but battered National Health Service turns 75

entertainment

entertainment

Wikipedia

leisure time